Thank you for Subscribing to Life Science Review Weekly Brief
ADMA starts the operation of its new plasma collection center in Conyers, Georgia.
FREMONT, CA: ADMA Biologics announces the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters plasma collection facility located in Conyers, Georgia. In connection with the plasma collection center opening, ADMA also announces the implementation of the Haemonetics Persona® Plasma Collection Solution for the NexSys PCS® system (Persona) across its plasma collection center network.
“We are pleased that ADMA has chosen to adopt the Haemonetics Persona® Plasma Collection Solution for the NexSys PCS® system. We share their commitment to a personalized and improved donor experience and striving to meet the growing demand for plasma-derived medicines to help patients in need," said Dr. Jan Hartmann, Chief Medical Officer of Haemonetics Corporation.
“The implementation of Persona® technology and the opening of ADMA’s newest plasma collection center directly advances the Company’s near term and ongoing strategic objectives,” said Adam Grossman, President and Chief Executive Officer of ADMA. “With the new plasma collection center opening, ADMA now has eight collection facilities under its corporate umbrella at various stages and remains on track to have 10 or more centers in operation by 2024. The anticipated yield enhancement resulting from Persona® implementation, in combination with our growing BioCenter network, has ADMA well-positioned to sustain quarter-over-quarter revenue growth throughout 2021 and beyond.
These activities will add to ensuring continuity of our commercial product supply to customers and patients in the growing Immune Globulin market.”
ADMA BioCenter’s newest, state-of-the-art plasma collection center located in Conyers, Georgia, features automated registration, high-tech collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly qualified and certified staff who put donor comfort and safety first. The center expects to manage a team of up to 50 highly trained healthcare workers at full capacity. Under updated United States Food and Drug Administration (FDA) guidance to obtain approval for plasma collection centers, sponsors are now expected to collect plasma donations for three months before submitting a Biologics License Application (BLA) filing. Accordingly, ADMA expects to file its BLA for the Conyers, Georgia plasma collection facility in approximately three months and expects a standard 12-month BLA review period by the FDA. In the meantime, ADMA is permitted to collect plasma donations at this site and, once the site is FDA approved, ADMA can use the plasma collected for further use in the manufacturing of life-saving therapies.